Gestational Trophoblastic Disease Market: Why 5.81% CAGR Changes Everything Through 2032
Navigating the Gestational Trophoblastic Disease Market: Strategic Trends and Commercial Horizons Through 2032 The global gestational trophoblastic disease (GTD) market has evolved from a niche oncology segment into a steadily expanding therapeutic arena, driven by advances in chemotherapy protocols, the emergence of immunotherapy options, and growing emphasis on fertility-preserving